Recombinant CD40-ligand

未知生产厂商

Recombinant CD40-ligand is under investigation in clinical trial NCT00053391 (Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma).

生成 AI 研报

医学正文保留数据源原文，避免将未经专业审核的机器翻译呈现为临床事实。

概览

Recombinant CD40-ligand is under investigation in clinical trial NCT00053391 (Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma).

技术标识符

UNII ID: T169OM1T8L

专利

每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。

RECOMBINANT PROTEINS WITH CD40 ACTIVATING PROPERTIES
US 2022175920 A1申请人: INST NAT SANTE RECH MED优先权: 2019
CN
EP
US
WO
5 件公开
DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
US 6923958 B2申请人: SCRIPPS RESEARCH INST优先权: 2002
US
4 件公开
METHODS AND COMPOSITIONS FOR ENHANCING VACCINE IMMUNE RESPONSES
EP 3639851 A1申请人: BAVARIAN NORDIC AS优先权: 2012
EP
US
3 件公开
Porcine reproductive and respiratory syndrome virus M protein and CD40L fusion vaccine and preparation method
CN 102908617 A申请人: GUANGZHOU GLAM BIOTECHNOLOGY CO LTD优先权: 2011
CN
Preparation method of CLEC9A+XCR1 + dendritic cells
CN 116376829 A申请人: ZHEJIANG FREE TRADE ZONE RUISAI BIOMEDICAL TECH CO LTD优先权: 2022
CN
FORMULATION OF ANTI-CD40L ANTIBODY AND PREPARATION METHOD FOR FORMULATION
WO 2026092379 A1申请人: INNOVENT BIOLOGICS SUZHOU CO LTD优先权: 2024
WO

药物